Docusign Envelope ID: D2451361-F72E-479F-A662-7C0D3347A5EE

CONTERA PHARMA

Justification Letter

Protocol Code Number:	JM-010CS-OL
EudraCT Number:	2022-002818-16
CT.gov ID:	NCT05516875
Sponsor:	Contera Pharma A/S
Study Title:	Open-Label Extension study of JM-010 in Parkinson's Disease Patients With Dyskinesia

To whom it may concern:

Contera Pharma A/S wishes to formally inform you of the early termination of this study. The termination was based on a business decision and not due to safety concerns or regulatory requirements. Additionally, we would like to notify you that the last visit of the final global patient occurred in Italy on June 27, 2024. The study aimed to recruit a total of 60 participants, with 6 participants enrolled from Spain and Italy. The study did not conduct any official data analysis regarding efficacy and safety.

DocuSigned by:
Minhee Cho
2B8332984E9F484...

10/28/2024

Minhee cho, Associate Director / Clinical Development Team

Date